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Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Despite increasing
treatment options for this disease, prognosis remains poor. CRIPTO (TDGF1) protein is expressed at high levels in
several human tumours and promotes oncogenic phenotype. Its expression has been correlated to poor prognosis
in HCC. In this study, we aimed to elucidate the basis for the effects of CRIPTO in HCC. We investigated CRIPTO
expression levels in three cohorts of clinical cirrhotic and HCC specimens. We addressed the role of CRIPTO
in hepatic tumourigenesis using Cre-loxP-controlled lentiviral vectors expressing CRIPTO in cell line-derived
xenografts. Responses to standard treatments (sorafenib, doxorubicin) were assessed directly on xenograft-derived
ex vivo tumour slices. CRIPTO-overexpressing patient-derived xenografts were established and used for ex vivo
drug response assays. The effects of sorafenib and doxorubicin treatment in combination with a CRIPTO pathway
inhibitor were tested in ex vivo cultures of xenograft models and 3D cultures. CRIPTO protein was found highly
expressed in human cirrhosis and hepatocellular carcinoma specimens but not in those of healthy participants.
Stable overexpression of CRIPTO in human HepG2 cells caused epithelial-to-mesenchymal transition, increased
expression of cancer stem cell markers, and enhanced cell proliferation and migration. HepG2-CRIPTO cells formed
tumours when injected into immune-compromised mice, whereas HepG2 cells lacking stable CRIPTO overexpression
did not. High-level CRIPTO expression in xenograft models was associated with resistance to sorafenib, which could
be modulated using a CRIPTO pathway inhibitor in ex vivo tumour slices. Our data suggest that a subgroup of
CRIPTO-expressing HCC patients may benefit from a combinatorial treatment scheme and that sorafenib resistance
may be circumvented by inhibition of the CRIPTO pathway.
Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
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Introduction
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related death worldwide [1]. In the
majority of cases, HCC arises on a background of
cirrhosis, which may be caused by chronic exposure
to damaging factors, such as chronic alcohol abuse,
hepatitis B or C, and various other chronic liver dis-
eases [2]. The invasive and metastatic potential of
HCCs is an important factor causing poor prognosis of
affected patients. Treatment options include resection
of the tumour, liver transplantation, minimal invasive
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image-guided oncologic therapies such as local ablation,
and transarterial therapies for the early and intermediate
tumour stages [3].
Targeted systemic treatments available for advanced
stage tumours or tumours progressing after loco-
regional therapies are the tyrosine kinase inhibitors
(TKIs) sorafenib (first-line) [4] and regorafenib
(second-line). Sorafenib is a tyrosine kinase (VEGFR,
PDGFR, RAF) inhibitor which delays HCC progression
and metastatic spread but is effective in only a minority
of patients and has severe side effects [4–7]. Recently,
it was shown that nivolumab, a programmed cell death
protein-1 (PD-1) checkpoint inhibitor, induces durable
objective responses in patients with advanced stage
HCC [8]. Due to a lack of biomarkers, it remains a
challenge to estimate the disease progression or respon-
siveness to therapies [4]. In addition to the high number
of non-responders to systemic therapy, there is a high
percentage of HCC patients who relapse after surgical
resection or minimal invasive oncological therapies. The
prognosis of HCC is often dismal, with a significant risk
of tumour recurrence or insufficient response to ther-
apies due to non-specificity of the treatments [9]. Cir-
culating α-fetoprotein (AFP) levels have been explored
as biomarkers in HCC [10]. However, detection of high
levels of AFP cannot be used for diagnosis or progno-
sis as it does not predict tumour size, stage, or HCC
progression, and is absent in 30% of HCC cases [10].
Elucidation of the basic mechanisms behind the invasive
and migration properties of HCCs and the identification
of markers that can predict therapeutic response and the
likelihood of recurrence are needed to identify suitable
personalized treatments. For example, identification
of sorafenib responders versus non-responders based
on biomarker expression and functional ex vivo assay
would allow better treatment selection.
CRIPTO (teratocarcinoma-derived growth factor 1;
TDGF1) is a GPI-anchored signalling protein and atyp-
ical member of the transforming growth factor (TGF)
gene family [11–13]. CRIPTO has multiple binding
partners and signalling functions [14,15]. It enables the
signalling of a subset of TGF-β superfamily ligands,
including NODAL [16], that require a co-receptor
(CRIPTO or Cryptic) to bind and assemble their type
I and type II signalling receptors [17]. CRIPTO also
inhibits other TGF-β superfamily ligands and atten-
uates cytostatic TGF-β1 signalling [12]. In addition,
CRIPTO can act independently of the TGF-β pathway
as a secreted factor that activates c-src/MAPK/Akt sig-
nalling, a pathway that is oncogenically mutated in liver
cancer [18]. Notably, each of these CRIPTO signalling
functions was shown to depend on CRIPTO binding to
cell surface glucose regulated protein 78 kDa (GRP78)
[19]. GRP78 is strongly induced by endoplasmic retic-
ulum (ER) stress and, like CRIPTO, plays key roles
in embryogenesis, stem cell regulation, and tumour
progression [20]. In addition to its physiological roles in
stem cells and embryogenesis, CRIPTO is an oncofetal
protein that is silenced postnatally. Re-expression is
often associated with pathological conditions such
as neoplasia of the breast, prostate, ovarian, blad-
der, colon, skin, lung, and brain [21–29]. Recently,
CRIPTO expression was correlated to poor survival
and tumour recurrence in HCC patients [30]. Moreover,
liver-specific deletion of GRP78 promoted maintenance
of tissue homeostasis and played a protective role during
ER-stress response, while elevated GRP78 levels were
associated with HCC progression [31–33].
In this study, we investigated CRIPTO expression in
HCC aiming to elucidate the effects of the CRIPTO
pathway while also exploring its potential use as a thera-
peutic target. We identified a potential role for CRIPTO
in therapy resistance to sorafenib, suggesting that com-
bination treatment with an inhibitor of the CRIPTO




Aetiopathological heterogeneity in tumours was taken
into account during the selection of HCC patient
material; in this study, we assessed specimens from
HCV infection-driven HCC (HCC-HCV, N= 4) and
alcoholic liver disease-driven HCC (HCC-ALD, N= 4).
Non-cirrhotic hepatitis C (HCV) tissues (N= 5) were
selected as controls. Selection of tissues was performed
in agreement with the ‘code of good practice’. Writ-
ten informed consent was obtained from each patient
included in the study. The study protocol conforms
to the ethical guidelines of the 1975 Declaration of
Helsinki as reflected in a priori approval by the insti-
tution’s Human Research Committee (B15.006/SH/sh,
biobank METC MDL/009/NV/nv). Tissue microarrays
(TMAs) used were from the Pathology Department
of University Hospital Basel (N= 234 tissue samples
including 33 HCC–adjacent tissue matched pairs) and
a commercially available TMA (BC03117; US Biomax,
Rockville, MD, USA; N= 69 tissue samples including
seven HCC–adjacent tissue matched pairs).
Animal models
Animal protocols were approved by the Committee for
Animal Experimentation and the Veterinary Authorities
of the Canton of Bern, Switzerland (BE55/16). Mice
received food and water ad libitum and were housed
in individually ventilated cages. NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ (NSG) mice were injected subcuta-
neously with 0.5 × 10E6 HepG2-CRIPTO (n= 4) or
HepG2-MOCK (n= 3) cells in Matrigel (354234; Corn-
ing, Kaiserslautern, Germany). Tumour growth was
monitored weekly. At week 12, mice were sacrificed
and tumours collected for further analysis.
Patient-derived xenograft (PDX)
A tumour needle biopsy from an anonymized advanced-
stage HCC patient was subcutaneously implanted
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in NSG mice and routinely passaged in vivo. A
zebrafish line [Tg(fli1:GFP)i114] was handled and
maintained according to local animal welfare regula-
tions to standard protocols (http: //www.ZFIN.org). Two
days post-fertilization (dpf), dechorionated zebrafish
embryos were anaesthetized and injected with approx-
imately 200 HepG2-MOCK or HepG2-CRIPTO cells
fluorescently labelled as described previously [34].
Two days after injection, the embryos were imaged
and clumps of cells (foci) counted. Zebrafish embryos
(including non-injected controls) were maintained at
33 ∘C, to compromise between the optimal tempera-
ture requirements for fish and mammalian cells. Data
are representative of/from at least two independent
and blind experiments with ≥ 30 embryos per group.
Foci were counted using Leica Application Suite X
software (version 1.1.0.12420; Leica Biosystems BV,
Amsterdam, The Netherlands).
Ex vivo tumour tissue culture and organoid
generation
Tissues from HCC PDX or HepG2-CRIPTO-derived
tumours were maintained in ex vivo cultures. Tissue
slices (150–200 μm) were cultured using Transwell
plates with an attached nitrocellulose membrane (Thin-
Cert #662640 inserts for 24-well plates, 0.4 μm pore
size; Greiner Bio-One, Kremsmünster, Austria) that
allowed contact of the tissue with the growth medium
but not the plastic in a manner that prevented alteration
of the tissue [35,36]. Culture plates were placed in a
sealed container saturated with oxygen, 40–50%, at
37 ∘C. Cultures were maintained for 7 days. Organoids
were derived from the bulk of PDX tumours similarly to
previously developed methods [37,38]. Single cell sus-
pensions were obtained by enzymatic homogenization
of the tissue by collagenase type II (Gibco, St-Sulpice
VD, Switzerland) (5 mg/ml) and Accutase (Sigma,
Buchs, Switzerland), followed by red blood cell lysis.
Organoids were maintained in low attachment plates
(Corning, Wiesbaden, Germany) in defined media
(supplementary material, Table S1). Tumour slices and
organoids were incubated for 7 and 2 days, respectively,
with dimethyl sulphoxide (DMSO, 0.1%), DMSO plus
Control-Fc antibody (2 μg/ml), sorafenib (1 μM), dox-
orubicin (1 μg/ml), and GRP78 N20 blocking peptide
(sc1050P, 2 μg/ml; Santa Cruz, LabForce, Muttenz,
Switzerland). After treatment, tissues were processed
for histology.
Cell lines and CRIPTO overexpression
The HepG2 cell line was maintained in Dulbecco’s
Modified Eagle medium (DMEM) supplemented with
10% fetal calf serum (FCS; Gibco) and 1% peni-
cillin/streptomycin (P/S; Invitrogen, Paisley, UK).
Lentiviral pTomo-mock [39] and pTomo-CRIPTO
constructs (provided by Dr P Gray; sequence from
ref 12) were used for HepG2 cell transduction. Selec-
tion of positive clones was based on red fluorescent
protein (RFP)-based cell sorting (FACS). Activation of
CRIPTO transcription was induced by lentivirus-CRE
transduction, which switched off RFP expression and
induced green fluorescent protein (GFP) expression.
Further information is provided in the supplementary
material, supplementary materials and methods.
Results
CRIPTO promotes a proliferative and mesenchymal
phenotype in in vitro HCC cells
CRIPTO has been shown to play an important role in
tumour development and progression in various cancer
types; however, its role in hepatic pathologies, such as
in HCC, remains understudied.
Firstly, we studied the functional effects of CRIPTO
in vitro, by stable overexpression of CRIPTO in HepG2,
an HCC-derived cell line with low tumourigenic-
ity in vivo [40]. We used a lentiviral red-to-green
pTOMO-CRIPTO construct in which CRE recombi-
nase activity excises a floxed RFP cassette, which turns
on CRIPTO expression and increases expression of
GFP [39]. A pTOMO-MOCK lentivirus lacking the
CRIPTO insert was used to generate a control cell
line (HepG2-MOCK). HepG2-CRIPTO cells trans-
duced with pTOMO-CRIPTO and CRE virus lacked
RFP expression and had GFP expression as predicted
(Figure 1A). HepG2-MOCK cells were also generated
in the presence of viral-mediated CRE and maintained
expression of RFP and weak GFP upon transduction,
whereas non-transduced cells (HepG2) showed no flu-
orochrome (Figure 1A). CRIPTO overexpression in the
HepG2-CRIPTO cells was confirmed at both the mRNA
(Figure 1B) and the protein level (supplementary mate-
rial, Figure S1A). The mRNA levels of NODAL and
GRP78, encoding CRIPTO interaction partners, were
both induced in HepG2-CRIPTO cells (Figure 1C,
D). GRP78 protein levels were reduced (supplementary
material, Figure S1B) and phosphorylated AKT (pAKT)
levels were increased, indicating downstream pathway
activation (supplementary material, Figure S1C) in
HepG2-CRIPTO cells. PCNA protein level differences
were minor (supplementary material, Figure S1D).
HepG2-CRIPTO cells acquired a more mesenchymal
phenotype relative to control cells (HepG2 WT and
HepG2-MOCK), as indicated by the downregulation of
E-CADHERIN (Figure 1E) and upregulation of EMT
markers such as VIMENTIN (VIM), ZEB-1, ZEB-2,
TWIST1, and SNAIL-2 (Figure 1F–J). HepG2-CRIPTO
cells exhibited higher expression of the cancer stem
cell (CSC) markers BMI1 and CD44 than control cells
(Figure 1L, M). EPCAM levels were also higher in
HepG2-CRIPTO cells, although this difference did not
reach statistical significance (Figure 1K). Additional
stemness marker expression was assessed at the mRNA
level: GLI-1, αv INTEGRIN (ITGAV), β3 INTEGRIN
(ITGB3), ALDH1A1, SOX2, and CD24 (supplementary
material, Figure S2A–F). HepG2-CRIPTO cells also
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had a higher proliferation rate (Figure 1N), enhanced
migration (Figure 1O), and wound closure properties
(Figure 1P) compared with control cells, in line with
EMT-associated gene expression (Figure 1E–J).
CRIPTO overexpression induces pro-tumourigenic in
vivo effects
We investigated possible effects of CRIPTO on the
cancer phenotype in vivo. HepG2-CRIPTO and HepG2-
MOCK cells were implanted subcutaneously in Matrigel
plugs in immunodeficient mice. Tumour formation was
observed at 5 weeks post-implantation; HepG2-MOCK
cells formed smaller tumours compared with the
HepG2-CRIPTO-bearing mice (Figure 2A). We iso-
lated single cells from the HepG2-CRIPTO tumour
tissues and selected CRIPTO-transduced cells based
on GFP expression (HepG2-CRIPTO-p1) (Figure 2B).
The single cells were then injected into the duct
of Cuvier of 2 dpf zebrafish embryos along with
the parental HepG2-CRIPTO and HepG2-MOCK
lines (Figure 2C, D) in order to determine their
potential to migrate and generate tumour foci in
vivo. HepG2-CRIPTO and HepG2-CRIPTO-p1 both
showed significantly more foci at 6 dpf relative to
HepG2-MOCK (Figure 2C). Histological analysis of
HepG2-MOCK and HepG2-CRIPTO tumour tissues,
grown as subcutaneous xenografts in mice, showed
different morphological structures (Figure 2E, F); only
HepG2-CRIPTO tumours resembled HCC morphology.
Both tumours showed similar levels of prolifera-
tion (PCNA) (Figure 2G–I) and HNF4a liver marker
expression (Figure 2J, K); however, different levels of
CRIPTO were observed (Figure 2L). HepG2-MOCK
xenograft tumours were distinguished by staining
for the epithelial marker E-CADHERIN (Figure 2M)
and absence of mesenchymal VIMENTIN expres-
sion (Figure 2O), in contrast to the HepG2-CRIPTO
tumours, which were E-CADHERIN-negative
(Figure 2N) and had VIMENTIN-positive areas
(Figure 2P). HepG2-CRIPTO tumours were cultured
ex vivo for 7 days, during which they were treated
with doxorubicin or sorafenib – two compounds that
are currently widely used in clinical practice for HCC
treatment – in the setting of transarterial chemoem-
bolization and oral therapy, respectively. Based on
H&E staining, both treatments (Figure 3C, D) led to
tissue damage compared with the untreated and vehicle
(DMSO) groups (Figure 3A, B). Immunofluorescence
analysis of proliferating cells (PCNA+; proliferating
cell nuclear antigen-positive) indicated that doxorubicin
treatment had a negative impact on tissue viability,
exhibited by the absence of PCNA+ cells (Figure 3G,
T). Sorafenib treatment showed areas of sustained
proliferation (Figure 3H, T).
The gene expression profiles of tumours treated ex
vivo with doxorubicin and sorafenib showed reduced
CRIPTO expression (Figure 3I) in both conditions
compared with control groups. However, CRIPTO
expression was higher in the sorafenib condition than
in the doxorubicin condition (Figure 3I). GRP78 levels
(Figure 3J) were not affected, compared with the vehi-
cle control. EPCAM and E-CADHERIN (CDH1) levels
were also reduced following doxorubicin and sorafenib
treatment (Figure 3K, N), while CD44 was increased
significantly in both drug treatments (Figure 3M). Inter-
estingly, only sorafenib induced expression of the stem
cell marker BMI1 (Figure 3L) and the EMT-associated
genes VIM and TWIST1 (Figure 3O, P). Expression of
the liver cancer stem cell marker CD24 was significantly
decreased upon sorafenib treatment (supplementary
material, Figure S2G). The induction of mesenchy-
mal (VIM, TWIST1) and stem cell markers (CD44,
BMI1) by sorafenib in the HepG2-CRIPTO tumour
slices may indicate an acquired aggressiveness due to
CRIPTO-related activation of a resistance mechanism
to sorafenib. To understand whether sorafenib resis-
tance pre-exists in the HepG2 or is linked to CRIPTO
overexpression, we assessed the proliferation rate of the
HepG2 parental, control MOCK, and HepG2-CRIPTO
cell lines in response to different sorafenib or dox-
orubicin concentrations. Proliferation, as assessed
using an MTS assay, was reduced in the doxorubicin-
and sorafenib-treated HepG2, HepG2-MOCK, and
HepG2-CRIPTO cell lines. Interestingly, HepG2 and
HepG2-MOCK cells proliferated less in the presence
of sorafenib (1 μM) compared with HepG2-CRIPTO
(Figure 3Q–S, 96 h).
CRIPTO may confer sorafenib resistance
To further investigate the role of CRIPTO in HCC, we
established a patient-derived xenograft (PDX) from
a needle biopsy obtained from a CRIPTO-expressing
advanced cancer stage HCC prior to patient treat-
ment with sorafenib (Figure 4A, B, original tumour
and PDX1). The PDX tissue (PDX2 and PDX3
tumours) maintained both HNF4a and CRIPTO
expression over time (Figure 4A, B), showing per-
sistent proliferation (Figure 4C, D) and minimal
apoptosis (Figure 4C, E) and HCC morphology
(Figure 4F, G).
To address whether CRIPTO inhibition increases
tumour responsiveness to sorafenib, we employed an
ex vivo tissue slice culture system. Tumour slices and
organoids derived from the PDX (from three different
passages) were treated with sorafenib; N20 (GRP78
blocking peptide), which blocks CRIPTO/GRP78 bind-
ing and CRIPTO signalling; or both in combination.
Treatment with N20 blocking peptide inhibited AKT
signalling activity, as shown by increased FOXO-luc
activity (supplementary material, Figure S1E). H&E
staining showed necrotic regions in all treatments in
various degrees (Figure 5C–F) compared with the orig-
inal and untreated condition, respectively (Figure 5A,
B). Proliferation (PCNA levels) was affected in both
single and combination treatments (Figure 5G–M).
However, treatment with sorafenib and N20 in
combination reduced cell proliferation (Figure 5L, M)
to a greater extent than treatment with either of the single
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Figure 1. In vitro effects of stable overexpression of CRIPTO in HepG2 cells. (A) Cell morphology of wild-type HepG2 cells; control, stably
overexpressing pTomo MOCK construct (MOCK, GFP+, RFP+); and stably overexpressing CRIPTO (CRIPTO, GFP+). Both cell lines were
transduced with pTOMO and CRE lentivirus. (B–D) RT-qPCR for mRNA expression of CRIPTO-associated members of the NODAL and GRP78
pathways in (B) CRIPTO (TDGF1), (C) NODAL, and (D) GRP78 mRNA expression (n= 3, ±SEM). Values were normalized to ACTB and to
control sample (ΔΔCt fold expression). (E–J) Levels of mRNA expression of epithelial-to-mesenchymal (EMT) markers in control, MOCK,
and overexpressing CRIPTO HepG2 cells were assessed by RT-qPCR. (E) E-CADHERIN (CDH1); (F) VIMENTIN (VIM); (G) ZEB-1; (H) ZEB-2; (I)
TWIST1; (J) SNAIL-2. Unpaired t-test; *p < 0.05. (K–M) mRNA expression levels of cancer stem cell (CSC) markers. (K) EPCAM; (L) BMI1;
(M) CD44. All values were normalized to ACTB and to control sample (ΔΔCt fold expression); n= 3; ±SEM. Unpaired t-test; *p < 0.05. (N)
Metabolic activity MTS assay (24, 48, 72, 96 h) was performed in control, MOCK, and CRIPTO-overexpressing HepG2 cells. Accumulation of
MTS was measured based on the absorbance at 490 nm. Values were normalized to the basal measurements at 0 h after cell seeding. The
graph represents values for three independent experiments (n= 3). Error bars indicate ±SEM. Two-way ANOVA; ***p < 0.001; ****p < 0.0001.
(O) Transwell migration assay of MOCK and CRIPTO-overexpressing HepG2 cells. Quantification of percentage positive area of migrated cells
(crystal violet cell dye) was performed in two independent experiments. Error bars indicate ±SEM. (P) Cell motility was assessed in wound
healing (scratch) assay. Wound size was quantified in a time-dependent manner (0, 24, 48, and 72 h) in three independent experiments.
Data were normalized to the 0 h time point; error bars indicate ±SEM. Unpaired t-test; *p < 0.05.
compounds alone. In organoid cultures derived from the
PDX tumour tissue, viability, measured by CellTiterGlo
assay, was also significantly reduced in the combination
treatment (Figure 5N–S), indicating a higher suscepti-
bility of sorafenib-resistant cells when CRIPTO-GRP78
signalling was blocked.
CRIPTO expression in human HCC
Expression of CRIPTO is present in embryonic tissues
and becomes silenced in postnatal tissues. Reactivation
of CRIPTO in adult tissues has been associated
with various cancer types and thus far, only one
study has investigated the role of CRIPTO in hepatic
malignancy. Considering the low expression of
CRIPTO at mRNA level and the absence of protein
levels in human liver tissues (both obtained from
http://www.proteinatlas.org), the role of CRIPTO in
homeostatic and pathological liver conditions merits
further investigation.
We determined the transcript levels of CRIPTO
(TDGF1) in normal human liver, tumour, and tumour-
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Figure 2. In vivo tumour formation is induced by overexpression of CRIPTO. (A) Subcutaneous tumour growth of HepG2-MOCK and
HepG2-CRIPTO cells in immunocompromised mice. Tumour volumes at endpoint were calculated with calliper measurement and using
the formula V = (L × W × W )/2. Average values from HepG2-MOCK (N= 3) and HepG2-CRIPTO (N= 4) are shown. Error bars indicate
±SEM. Unpaired t-test; *p < 0.05. (B–D) GFP-positive HepG2-CRIPTO cells (p1) from the tumours were collected and injected in zebrafish to
monitor cell migration and tumour growth (C, D) along with HepG2-MOCK and HepG2-CRIPTO cells. (E, F) Haematoxylin and eosin staining
representative of the HepG2-MOCK and HepG2-CRIPTO tumours. Scale bars: 100 μm (top); 50 μm (bottom). (G–I) Immunofluorescence
for PCNA (red) and cleaved caspase-3 (green) in HepG2-MOCK (G) and HepG2-CRIPTO (H) tumour sections. Scale bars: 50 μm. (I)
Quantification of PCNA-positive area normalized to nuclei surface area and represented as fold change over the HepG2-MOCK samples.
(J, K) Immunofluorescence for HNF4a (grey) and CRIPTO (green) in HepG2-MOCK and HepG2-CRIPTO tumour sections. Scale bars: 50 μm.
(L) Quantification of CRIPTO expression (positive stained area normalized to nuclei surface area); fold change HepG2-MOCK values. (M, N)
Immunofluorescence for the epithelial marker E-CADHERIN (red) in HepG2-MOCK and HepG2-CRIPTO tumour sections. Scale bars: 50 μm.
(O, P). Immunofluorescence for the mesenchymal marker VIMENTIN (green) in HepG2-MOCK and HepG2-CRIPTO tumour sections. Scale
bars: 50 μm.
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Figure 3. Ex vivo drug response to doxorubicin and sorafenib treatments indicates differential proliferation. EMT and CSC marker expression
in CRIPTOhigh tumour slices ex vivo. (A–D) Ex vivo culture of HepG2-CRIPTO tumour slices; H&E staining of untreated part (A), DMSO vehicle
(B), doxorubicin (1 μg/ml) (C), and sorafenib (1 μM) (D) treated. Scale bars: 100 μm (top); 50 μm (bottom). (E–H) Immunofluorescence of
PCNA (red) staining on ex vivo cultured tissue parts; untreated part (E), DMSO vehicle (F), doxorubicin (G), and sorafenib (H) treated. DAPI
marks the nuclei (blue). Scale bars: 50 μm. (I–P) Levels of mRNA for (I) CRIPTO, (J) GRP78, (K) EPCAM, (L) BMI1, (M) CD44, (N) E-CADHERIN,
(O) VIMENTIN, and (P) TWIST1 in HepG2-CRIPTO tumours (untreated) exposed to vehicle (DMSO), doxorubicin (1 μg/ml) (C), and sorafenib
(1 μM). Unpaired t-test; *p < 0.05; **p < 0.01. (Q–S) Metabolic activity MTS assay (24, 48, 72, 96 h) was performed in control (Q), MOCK-
(R) and CRIPTO-overexpressing HepG2 cells (S). Cells were exposed to sorafenib (1 or 5 μM) and doxorubicin (1 or 5 μg/ml). Values are
normalized to the basal measurements at 0 h after cell seeding. Graph represents values for three independent experiments (n= 3). Error
bars indicate ±SEM. Two-way ANOVA; ***p < 0.001; ****p < 0.0001. (T) Quantification of immunofluorescence staining. Mean percentage
of PCNA-positive area, normalized to the nuclei (DAPI-positive area). Error bars indicate ±SD.
adjacent tissues by RT-qPCR. Expression was low
to undetectable in normal samples (N= 8) compared
with both tumour (N= 7, Table 1) and tumour-adjacent
(N= 7, cirrhotic, Table 1) tissues, which showed similar
levels, indicating that increased CRIPTO expression
is possibly associated with pre-existing chronic liver
disease.
To better understand the expression pattern of
CRIPTO in disease states, we determined the pro-
tein expression in a tissue microarray (TMA Basel
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Figure 4. Establishment of CRIPTO-positive patient-derived xenograft model. (A) Immunofluorescence staining for HNF4a (grey) and CRIPTO
(green) expression in an HCC tumour sample (left), HCC PDX first passage (PDX1), second passage (PDX2, centre), and third passage (PDX3,
right). (B) Quantification of CRIPTO immunofluorescence staining in the PDX tumours represented as fold change the original tumour tissue
expression values. Error bars indicate ±SEM. (C) Immunofluorescence staining for PCNA (red) and cleaved CASP3 (green) expression in an
HCC tumour sample (left), HCC PDX first passage (PDX1), second passage (PDX2, centre), and third passage (PDX3, right). (D) Quantification
of PCNA and (E) cleaved CASPASE 3 (CASP3) immunofluorescence staining in the PDX tumours represented as fold change over the original
tumour tissue expression values. Error bars indicate ±SEM. (F, G) H&E staining at 10× (F) and at 40× objective (G) magnification; HCC
tumour sample (left), HCC PDX first passage (PDX1), HCC PDX second passage (PDX2, centre) and third passage (PDX3, right). Scale bars 50:
panels A, C and G. Scale bars 100: panel F.
university cohort, 234 tissue samples) by immunohis-
tochemistry and found that HCC tissue (N= 128) had
significantly (p= 0.0389) less CRIPTO expression than
non-HCC tissue (N= 106) (Figure 6B and Table 2).
The non-HCC cases reflect unpaired, tumour-adjacent
tissues from fibrosis, cirrhosis, and low-grade and
high-grade dysplastic nodule cases (supplementary
material, Figure S3A), thus not healthy liver tis-
sues. Within this TMA, we also analysed paired,
matched cases of tumour and adjacent non-tumour
tissue (N= 33) corresponding to the same patients and
found that the CRIPTO levels were similar in both cases
(Figure 6H and Table 3). A second TMA (US Biomax)
was used for the validation of these results and we
confirmed CRIPTO expression in both tumour-adjacent
cirrhotic tissues and tumour (HCC) tissue, as in the
first TMA (supplementary material, Figure S3B, and
Tables 2 and 3).
Next, we evaluated CRIPTO and GRP78 expres-
sion by immunofluorescent staining in tumours
of resected human livers from HCC and adjacent
cirrhotic (non-tumour) tissues (N= 8) and in
non-cirrhotic tissues (N= 5, HCV infection). Clini-
cal and tumour characteristics are shown in Table 2 (all
cases) and Table 3 (matched cases). CRIPTO expres-
sion was detected at higher levels in the tumour than
in adjacent cirrhotic non-tumour tissue in two out of
four patients with HCV-related disease (Figure 6D,
E) and in two out of four ALD-related HCC patients
(N= 4) (Figure 6G, H). In non-cirrhotic HCV sam-
ples, we observed that expression levels of CRIPTO
were lower than those of the tumour-adjacent groups
(Figure 6E).
The CRIPTO binding and signalling partner GRP78
was expressed in a similar pattern with CRIPTO
in hepatocytes. Quantification indicated that higher
GRP78 expression in tumour tissue, as compared with
adjacent non-tumorous tissue, was detected in one
HCV-related (Figure 6D, F) and two ALD-related HCC
patients (Figure 6G, I). In matched cases in all three
TMA datasets that we have analysed here, we detected
CRIPTO expression in HCC specimens both in the
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Figure 5. Sorafenib resistance may be circumvented by CRIPTO pathway inhibitor in an ex vivo culture model of HCC PDX. (A–F) Ex vivo
tissue culture of HCC tumour tissue slices from PDX4 of the established PDX. Drug treatments were performed during the 7 days of ex vivo
cultures. (A) Original tissue (non-cultured); (B) untreated; (C) vehicle (DMSO 0.1%) plus Control-Fc (2 μg/ml); (D) N20 blocking peptide
(2 μg/ml); (E) sorafenib (1 μM); (F) sorafenib (1 μM) plus N20 (2 μg/ml). (G–L) Immunofluorescence staining for PCNA (red) and cleaved
caspase-3 (green) expression. DAPI: nuclear dye. (G) Original tissue (non-cultured); (H) untreated, (I) vehicle (DMSO 0.1%) plus Control-Fc
(2 μg/ml); (J) N20 blocking peptide (2 μg/ml); (K) sorafenib (1 μM); (L) sorafenib (1 μM) plus N20 (2 μg/ml). (M) Quantification of PCNA
immunofluorescence staining. Mean percentage of PCNA-positive area, normalized to the nuclei (DAPI-positive area). Error bars indicate
±SEM; n= 3 independent experiments. Paired t-test; *p < 0.05. (N–R) Bright-field images showing the morphology of organoids derived
from the HCC PDX after 48 h of culture (N, untreated), and after treatments with (O) DMSO plus Control-Fc, (P) N20 (2 μg/ml), (Q) sorafenib
(1 μM) or (R) sorafenib (1 μM) plus N20 (2 μg/ml). (S) CellTiter Glo viability luciferase-based assay measuring ATP content in organoids
derived from HCC PDX tumour. Organoids were treated with DMSO plus Control-Fc, N20 (2 μg/ml), sorafenib (1 μM) or sorafenib (1 μM) plus
N20 (2 μg/ml) for 48 h. Error bars indicate ±SD. Ordinary one-way ANOVA; **p < 0.01.
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Table 1. Clinical parameters of the specimens used from the
LUMC cohort for mRNA analysis. The list corresponds to Figure 6A
qPCR cases LUMC (N = 15)
Gender, male, N (%) 11 (73.3%)
Age (range), years 72 (59–74.5)
Control (no underlying liver disease) 8 (53.3%)
Adjacent and HCC matched samples
Fibrosis–cirrhosis (yes), N (%) 7 (46.6%)





n.a. = not applicable.
tumour and in the tumour-adjacent tissue – however,
at different levels – and identified three subgroups of
CRIPTO-expressing HCCs (Table 4).
Given the low expression of CRIPTO in non-cirrhotic
samples (Figure 6A, E) and the high expression already
in tumour-adjacent cirrhotic tissue, we accessed the
transcript levels of CRIPTO in three microarray
datasets [41–43] (publicly available data from the
Oncomine database, https://www.oncomine.org). Com-
parison among normal liver, cirrhosis, HCC, and liver
cell dysplasia indicated that HCC cases had statis-
tically significantly higher CRIPTO mRNA levels
versus normal liver tissues in all datasets (Figure 6J–L;
p≤ 0.01). Cirrhotic cases showed non-significant
changes (Figure 6J, L), while liver cell dysplasia
showed significantly higher levels versus normal liver
expression levels (Figure 6L).
The data above highlight that in individual HCC cases,
evaluation of the tumour-adjacent tissue is informative
but cannot be considered as control. CRIPTO expression
is upregulated in many cases of pathological conditions
(cirrhosis, dysplasia); thus, absolute expression levels
of CRIPTO in liver tissues should be compared with
reference levels from healthy tissues, and not cirrhotic,
tumour-adjacent counterparts.
Discussion
CRIPTO is a cell surface protein that regulates sig-
nalling of TGF-β superfamily ligands and also has
EGF-like activity. It is a small glycosylphosphatidyli-
nositol (GPI)-anchored cell surface/secreted oncopro-
tein that plays important roles in regulating stem cell dif-
ferentiation, embryogenesis, tissue growth, and remod-
elling [14]. The tumour-promoting role of CRIPTO has
been documented in multiple malignancies, including
those characterized by osteotropism in their metastatic
stage, such as breast and prostate cancer [25,44,45].
Recently, higher CRIPTO expression was detected in a
cohort of HCC patients (49.8%, N= 205), and which
correlated with poor prognosis [30].
We showed that CRIPTO expression in tumours was
mainly detected in areas lining the stromal compartment.
This is not surprising given its role in promoting EMT,
which we and other groups have shown for other cancer
types [46]. The CRIPTO-positive tumour cells adjacent
to the stroma may enter the circulation and be respon-
sible for metastatic spread. However, further studies are
necessary to corroborate this hypothesis.
Interestingly, in the TMAs (Basel and US Biomax)
that we analysed, CRIPTO protein expression was
higher in the non-tumour tissue than in tumour tissue.
The same trend was observed in a smaller cohort of
adjacent and tumour tissue in matched cases of the
TMAs, although the number of available matched pairs
in the present study may be too small to draw firm
conclusions.
Given the fact that the non-tumour tissues have a cir-
rhotic background and CRIPTO is not expressed dur-
ing homeostasis, it could be speculated that CRIPTO
correlates to disease progression [30,40]. Moreover, it
should be noted that tissue sections (cores) available in
the TMAs have a small size, without information of the
exact location of where it was derived from within the
tumour tissue. The LUMC cohort of matched cases con-
tained large tissue areas derived from a histopathologi-
cally confirmed area (tumour, tumour-adjacent), as eval-
uated by a certified pathologist. It needs to be empha-
sized that HCCs are heterogeneous tumours and there-
fore the results of this study should be validated in larger
numbers of matched larger tissue sections. Using a tran-
scriptomic approach, we showed that CRIPTO mRNA
expression is progressively elevated in pathological hep-
atic conditions such as HCC and liver cell dysplasia
compared with normal state, as assessed in three distinct
datasets (Oncomine).
In line with the human data, stable overexpression
of CRIPTO in HepG2 cells led to a more aggressive
tumour phenotype in vitro, ex vivo and in vivo char-
acterized by EMT, mesenchymal phenotype, as well
as stem cell characteristics as determined by histol-
ogy and transcript level alterations. Our data support
the notion that CRIPTO plays a role in cirrhosis as
well as tumour initiation and aggressiveness by increas-
ing cellular plasticity and stem cell properties simi-
lar to what we have also shown recently for prostate
cancer [34].
Elevated CRIPTO levels in both HCC and the cir-
rhotic, potentially premalignant, state suggest that
targeted inhibition of CRIPTO could be beneficial in
combination with chemical compounds currently used
in clinical practice. Doxorubicin is a single-agent drug
that has been the most studied chemotherapy agent for
advanced HCC [47]. Despite initial studies showing
high response rates, subsequent studies showed only a
small survival advantage. It is currently widely used for
trans-arterial chemoembolization. The development of
combination therapy using molecularly targeting drugs
such as sorafenib might be useful for the prevention
of early HCC metastasis. Given that sorafenib is the
standard of care in advanced stage HCC but provides
only a 3-month median survival benefit in advanced
stage HCC [46] and no survival benefit in combination
with doxorubicin (clinical trial phase III NCT01015833
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Figure 6. Expression of CRIPTO and its signalling partner GRP78 in human HCC liver tissues. (A) CRIPTO mRNA levels in tissue from healthy
liver tissues (N= 8), tumour (N= 7), and tumour-adjacent tissue (N= 7) matched cases; values are normalized to the average of the control
samples (ΔΔCt fold). (B) CRIPTO staining scoring in tissue microarray (TMA#1) samples; non-HCC (N= 106) versus HCC cases (N= 128).
(C) CRIPTO protein expression in the cohort of 19 matched (tumour versus tumour-adjacent tissue) cases of TMA#1. (D–F) Representative
immunofluorescence images of CRIPTO and GRP78 staining in human liver sections from HCV-derived HCC tissue (HCV infection-driven) and
adjacent non-tumour control tissue from the same patient. Nuclei are stained with TO-PRO-3 (blue). Scale bars: 75 μm. Quantification of
protein expression of CRIPTO (E) and GRP78 (F), determined by immunofluorescence in HCC HCV tumour (Tumour) or adjacent non-tumour
tissue (Control) from the same patient (N= 4). Liver tissue from patients with HCV infection but absence of fibrosis (non-cirrhotic HCV,
N= 4) was used for comparison. The percentage of positive pixel area was the average from two to four focal areas per section. Each
bar represents values from each patient. Error bars indicate ±SD. (G–I) Representative immunofluorescence images of CRIPTO and GRP78
protein expression in human liver sections from alcoholic liver disease (ALD)-derived HCC tissue and adjacent non-tumour control tissue
from the same patient. Nuclei are stained with TO-PRO-3 (blue). Scale bars: 75 μm. Quantification of (H) CRIPTO and (I) GRP78 protein
expression as assessed by immunofluorescence in tumour HCC ALD (Tumour) and adjacent non-tumour tissue (Control) from the same
patient (N= 4). The percentage of positive area (pixels) was the average from two to four focal areas per section. Each bar represents
values from each patient. Error bars indicate ±SD. (J–L) Transcript levels for CRIPTO in liver tissues from normal, cirrhosis, HCC, and liver
dysplasia conditions. Data were obtained from three distinct publicly available datasets (GSE14323 [42], GSE14520 [43], and GSE6764 [41]),
accessed through the Oncomine database (https://www.oncomine.org). Statistical analysis and P values were obtained from the Oncomine
plots.
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Table 2. Baseline characteristics of patients (staining samples). Patient samples correspond to Figure 6B and supplementary material,
Figure S3A (TMA Basel); Figure 6D–I (LUMC); and supplementary material, Figure S3B (TMA US Biomax). Median (IQR). n.a. = not
applicable. Only the cases with known clinical background are included in this table
Staining cases LUMC (N = 13) TMA Basel (N = 163) TMA US Biomax (N = 62)
Cohort with clinical background, N (%) 13 (100%) 76 (46.6%) 62 (100%)
Gender, male, N (%) 13 (100%) 58 (35.6%) 52 (83.9%)
Age (range), years 54 (47–63) 76 (67–80) 53 (45–59)
Fibrosis–cirrhosis
Yes/undefined, N (%)
8 (61.5%)/n.a. 38 (23.3%)/9 (5.5%) 62 (100%)/n.a.
Patients with HCC, N (%) 8 (61.5%) 46 (28.2%) 48 (77.4%)
T1 (N) 1 15 1
T2 (N) 5 12 18
T3 (N) 2 18 25
T4 (N) n.a. 1 4
Unknown clinical background n.a. 87 (53.4%) n.a.
Patients with HCC, N (%) n.a. 82 (50.3%) n.a.
Fibrosis–cirrhosis
Yes/undefined, N (%)
n.a. 49 (30.1%)/10 (6.1%) n.a.
Table 3. Baseline characteristics. Patient samples correspond to the matched tumour versus tumour-adjacent tissues of Figure 1A–F
(LUMC); Figure 1H (TMA Basel); and supplementary material, Figure S3 (TMA US Biomax). Median (IQR). n.a. = not applicable
Matched cases LUMC (N = 8) TMA Basel (N = 33) TMA US Biomax (N = 7)
Gender (male), N (%) 8 (100%) 26 (78.8%) 6 (85.7%)
Age (range), years 56.5 (51–63) 77 (68–80.5) 52 (48–54)
Fibrosis–cirrhosis
Yes/undefined, N (%)
8 (100%) 27 (81.8%)/6(18.1%) 7 (100%)
TNM stage, N (%)
T1 1 (12.5%) 11 (33.3%) n.a.
T2 5 (62.5%) 7 (21.2%) 2 (28.6%)
T3 2 (25%) 15 (45.5%) 4 (57.1%)
T4 n.a. n.a. 1 (14.3%)
[48]), we explored the possible role of CRIPTO in
sorafenib resistance. A low dose of sorafenib did not
affect the proliferation of HepG2-CRIPTO cells. These
results suggest that CRIPTO causes a differential drug
response and refractoriness to sorafenib. This possibil-
ity was supported by our finding that HepG2-CRIPTO
tumours cultured ex vivo possessed areas of proliferating
cells following sorafenib treatment.
PDX tissue slices cultured ex vivo showed no sensi-
tivity to sorafenib. However, the combination treatment
with the N20 peptide, which blocks CRIPTO signalling,
showed a significant reduction of proliferation and
no effect on apoptosis. This suggests that it might be
beneficial to employ a combination of treatments that
target either CRIPTO directly or one of its downstream
signalling mediators, e.g. ERK and AKT pathways,
in order to achieve an inhibition of proliferation in
the HCC tumour cells. Similarly, organoids derived
from the PDX tumour tissue, treated in the same con-
ditions as the ex vivo cultures, showed a reduction in
viability when treated with both N20 and sorafenib.
This suggests that inhibition of CRIPTO/GRP78 sig-
nalling specifically enhances the response to sorafenib.
Mechanistically, this effect can be explained by the
fact that PI3K/AKT kinase, which is downstream of
CRIPTO/GRP78, is also involved in the acquisition
of resistance after long exposure to sorafenib [49],
while inhibition of AKT may resensitize tumour cells
[50]. CRIPTO has been implicated in therapy resis-
tance in lung cancer, with studies showing that high
CRIPTO expression correlates with lower sensitivity
to treatment with EGFR kinase inhibitors [51,52].
Modulation of CRIPTO expression or downstream
(SRC, AKT) signalling reverses the resistance to
EGFR inhibitors [52].
The results presented in this study show that CRIPTO
signalling increases proliferation and seems to be
required for tumour progression, as suggested for
both prostate and breast cancer. Our findings suggest
that blocking CRIPTO signalling may have thera-
peutic benefit in combination with existing therapies
for HCC.
Table 4. Comparison of CRIPTO expression in the different cohorts of tumour versus tumour-adjacent tissue (matched cases)
Matched tissue samples LUMC (N = 8) TMA Basel (N = 33) TMA US Biomax (N = 7)
Cripto tumour < Cripto adjacent tissue, N (%) 2 (25%) 16 (48.5%) 5 (71.4%)
Cripto tumour= Cripto adjacent tissue, N (%) 0 (0%) 8 (24.2%) 1 (14.3%)
Cripto tumour > Cripto adjacent tissue, N (%) 6 (75%) 9 (27.3%) 1 (14.3%)
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